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Abstract: We report a case of acute demyelinating encephalitis that occurred after viral 
vaccination against hepatitis A-, hepatitis B-, and poliovirus and vaccination against bacterial 
toxins of diphtheria and tetanus. After different diagnosis had been excluded, we diagnosed 
postvaccinal demyelinating encephalitis and started treatment with high dose intravenous 
methylprednisolone, followed by peroral application in decreasing dosages for three weeks. 
A few days after the treatment with methylprednisolone had been ﬁ  nished, the patient’s medical 
condition deteriorated again. Thus, we initiated plasma exchange at an advanced state of illness, 
which led to signiﬁ  cant continuous improvement. The role of plasma exchange is discussed 
controversially, in particular the issue of timing. We report a case that shows improvement due 
to plasmapheresis several weeks after symptom onset.
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The incidence and significance of autoimmune central nervous system (CNS) 
manifestations after vaccination remain unknown (Schattner 2005). Acute disseminated 
encephalomyelitis (ADEM), an acute or subacute disease characterized by the occur-
rence of multifocal neurological deﬁ  cits, was observed from one up to several weeks 
after vaccination (Gout 2001). Several cases of ADEM were described after active 
vaccinations against hepatitis B (Kaplanski et al 1995; Pirmohamed and Winstanley 
1997; Tourbah et al 1999; Cabrera-Gomez et al 2002), pertussis (Sriram and Steinman 
1984), diphtheria-tetanus-poliomyelitis (Mancini et al 1996), smallpox, yellow fever, 
typhoid fever, tuberculosis, and rabies (Gamboa et al 1983; Miller et al 1967). Here, 
we report a patient with acute demyelinating encephalitis that occurred after active 
vaccination.
A 46-year-old male patient presented in a community hospital with fever, visual 
hallucinations, tonic-clonic seizures and progressive amnestic impairment three weeks 
after active vaccination with recombinant hepatitis A- and hepatitis B-virus, diphteria, 
tetanus, and poliovirus antigen. These multiple vaccinations were given on one day 
due to the urgent travel plans of the patient. The patient’s medical- and family his-
tory was unremarkable without any history of multiple sclerosis, seizures, or other 
neurological diseases. Tentative diagnosis during ﬁ  rst external hospitalization was 
limbic encephalitis. The patient received acyclovir and anticonvulsive medication 
with carbamazepine. He did not obtain any immunomodulatory treatment and the 
further diagnostic examination did not reveal any signs of malignancy. Due to further 
progression, the patient was presented in our hospital ten weeks after symptom onset. 
The neurological examination revealed a central facial paresis, tongue deviation to 
the right side, dysarthria, and severe dysphagia, which required tracheostomy. Cra-
nial magnetic resonance imaging (MRI) showed multiple white matter lesions with Neuropsychiatric Disease and Treatment 2007:3(6) 988
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Gadolinium enhancement in the left temporal lobe, but lack 
of MRI changes in the brainstem (see Figure 2). Analysis of 
cerebrospinal ﬂ  uid (CSF) yielded pleocytosis with 12 lym-
phocytes per microlitre with autochthone oligoclonal bands 
compared to serum bands. A speciﬁ  c causative pathogen 
by extensive microbiological CSF analysis could not be 
obtained. 18-ﬂ  uorodeoxyglucose PET/CT showed a focal 
metabolic enhancement of the white matter lesions in the 
temporal lobe. Metabolism of the left temporal and parietal 
lobes was reduced. Stereotactic biopsy of one of the white 
matter lesions identiﬁ  ed inﬂ  ammatory demyelination with-
out any signs of speciﬁ  c inﬂ  ammation or malignancy (see 
Figure 1). We repeatedly performed thorax and abdomen 
CT scan, abdomen sonography, gastroscopy, colonoscopy, 
bronchoscopy, urological examination, and determination of 
serum analytic markers including tumor markers and speciﬁ  c 
antibodies to exclude paraneoplastic genesis (see Table 1). 
We repeatedly performed microbiological blood and CSF 
assays to exclude parainfectious disease. Any laboratory 
tests were without pathological ﬁ  ndings.
We hereby excluded other differential diagnosis such as 
herpes simplex encephalitis, Hashimoto encephalitis, and 
limbic encephalitis. Assuming a postvaccinal demyelinating 
encephalitis we started intravenous treatment with 
methylprednisolone for a period of 5-days, 1000 mg a day, 
followed by oral methylprednisolone with decreasing dosages 
for three weeks. This treatment with methylprednisolone was 
initiated 11-weeks after symptom onset. Methylprednisolone 
treatment resulted in a temporary slight improvement of 
the amnestic impairment. During the methylprednisolone 
treatment, the patient’s condition deteriorated again with 
short-term and long-term memory disturbances and progres-
sive reduction of alertness and concentration. Furthermore, 
the patient revealed reduced vigilance. We decided to initi-
ate plasma exchange 13-weeks after symptom onset, ﬁ  ve 
treatments within 10-days. A few days after initiation of 
this therapy neurological improvement subsequently com-
menced. Afterwards the patient was alert following common 
and more complex requests. The patient did not receive other 
immunosuppressive drugs or intravenous preparations of 
immune globulin (IVIG).
Four months later, follow-up examination revealed the cur-
ing of the amnestic impairment. The patient had not suffered 
from any further epileptic seizures. Cranial MRI scans revealed 
a reduction of the white matter lesion size. However, dysphagia 
persisted, therefore, tracheostoma was still mandatory.
The risk of postvaccinal autoimmune inﬂ  ammatory CNS 
demyelination is unknown but certainly rare. The probable 
pathogenetic mechanism is a molecular mimicry between 
vaccine proteins and myelin components. Cross-reactivity 
of HbsAg with a myelin peptide derived from a proteolipid 
protein (PLP) has been demonstrated (Gran et al 2000).
In our case, we suggest that the patient acquired an acute 
demyelinating encephalitis in consequence of vaccination 
against HAV, HBV, diphtheria, tetanus and poliovirus. The 
multiple temporal white matter lesions in combination with 
seizures and amnestic disorder could also be consistent with a 
diagnosis of limbic encephalitis. Further relevant differential 
diagnoses in our patient could be herpes simplex encephalitis 
and Hashimoto encephalitis. But the medical history, the 
diagnostic ﬁ  ndings (Table 1) including normal levels of 
thyroid antibodies and negative herpes-virus PCR-screening, 
and the repeated exclusion of malignancy make it most likely 
that the encephalitis was caused by the vaccination.
We could not prove the causative antigen which could 
appear after all ﬁ  ve antigens. But we consider that the 
combination of these multiple vaccinations given on one 
day are probably sufﬁ  cient to trigger this severe autoim-
mune inﬂ  ammatory CNS demyelination. In the early 1990s, 
several cases of patients with CNS demyelination events 
within eight weeks after recombinant hepatitis B (HB) vac-
cine injection have been described (Kaplanski et al 1995; 
Pirmohamed and Winstanley 1997; Tourbah et al 1999; 
Cabrera-Gomez et al 2002). Thus, we suspect that the HB 
vaccine essentially contributed to the postvaccinal reaction. 
To our knowledge, it had never been reported a case with 
postvaccinal demyelinating encephalitis triggered by multiple 
vaccinations given at one day.
Methylprednisolone treatment initially resulted in a slight 
improvement. But the patient’s condition deteriorated already 
during this therapy. The time course of the improvement 
starting a few days after the beginning of plasma exchange 
suggest that the improvement can be ascribed to plasma 
exchange therapy. The observed time course reduced the 
assumption that a delayed effect of steroid treatment or 
the natural course of disease have crucially contributed to 
the recovery of our patient.
Accepted treatment methods of acute CNS demyelination 
include intravenous methylprednisolone, immunoglobulines 
or a combination of both (Tselis 2001). Few reports 
highlight the importance of plasmapheresis in ADEM 
(Kanter et al 1995; Lin et al 2004). The preferential treatment 
effect of methylprednisolone is a suppression of T-cell 
mediated immune response. After non-response to steroid 
treatment, the removal of B-cell mediated immunoglobulines 
and circulating antibodies from the serum using plasma Neuropsychiatric Disease and Treatment 2007:3(6) 989
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Figure 1 Histopathological examination of the biopsy sample revealed an inﬂ  ammatory demyelinating lesion with perivascular lymphocytes and numerous macrophages 
(immunohistochemical staining for CD68).
Figure 2 Axial (a) and coronar (b) FLAIR sequence showing a hyperintensive signal with gadolinium enhancement (b) in the left temporal lobe. Relevant radiological 
differential diagnosis are herpes simplex encephalitis, Hashimoto encephalitis, and limbic encephalitis.Neuropsychiatric Disease and Treatment 2007:3(6) 990
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exchange seems to be obvious. Moreover, plasmapheresis 
also affects the balance of T helper type-1 and T helper 
type-2 cells of circulating peripheral lymphocytes in 
patients with neuroimmunological diseases (Goto et al 
2001). In cases of acute CNS demyelination, treatment with 
plasmapheresis was suggested to be beneﬁ  cial (Kanter et al 
1995; RamachandranNair et al 2005). In a retrospective 
analysis of Keegan (2002), 59 consecutive patients had been 
treated with plasmapheresis for acute CNS demyelination, 
including 10 patients with ADEM (Keegan et al 2002). 
Beneﬁ  cial therapeutic response had been obtained, even 
when plasmapheresis had been initiated 60-days after onset 
of neurological symptoms. However, it remains unclear 
if the improved patients had ADEM or other acute severe 
demyelinating diseases. It was also not reported if one of the 
patients acquired ADEM after vaccination. Others report a 
clear improvement in ﬁ  ve of six patients with acute steroid-
insensitive inﬂ  ammatory CNS demyelinations due to treat-
ment with plasma exchange (Bennetto et al 2004). However, 
in this article four patients had MS, one patient had acute 
transverse myelitis, one had clinical isolated optico-spinal 
syndrome, and none of the patients suffered from ADEM. 
There are only a few reports which address the effect of 
plasma exchange in ADEM depending on an advanced illness 
stage (Lin et al 2004; RamachandranNair et al 2005). Lin and 
colleagues analyzed 14 patients treated with plasma exchange 
for ADEM. Plasmapheresis was initiated with a range of 
3–18 days after symptom onset and improvement began three 
days after initiation (Lin et al 2004). RamachandranNair 
reported two cases which demonstrated that plasma exchange 
could be useful even in the ﬁ  fth week of severe ADEM not 
responding to steroid therapy (RamachandranNair et al 
2005). However, to our knowledge there are no reported 
cases of postvaccinal ADEM where the beneﬁ  ts of plasma 
exchange were seen in such a late disease course more than 
13-weeks after symptom onset.
Standard therapy for acute severe demyelinating 
encephalitis is high dose intravenous corticosteroids. For 
patients who fail to improve with this regime, a plasma 
exchange should be considered. Here we report a case of 
postvaccinal demyelination with rapidly repeated progression 
after treatment with methylprednisolone. In our case, we 
show an improvement due to plasmapheresis more than 
3-months after symptom onset. This resulted in a remarkable 
amelioration of neurological outcome.
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